The estimated Net Worth of Luisa Puche is at least $512 Tysiąc dollars as of 7 January 2020. Ms. Puche owns over 5,000 units of Enochian Biosciences Inc stock worth over $3,500 and over the last 5 years she sold ENOB stock worth over $0. In addition, she makes $508,791 as Chief Financial Officer at Enochian Biosciences Inc.
Sign up
Ms. Puche ENOB stock SEC Form 4 insiders trading
Luisa has made over 1 trades of the Enochian Biosciences Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently she exercised 5,000 units of ENOB stock worth $3,500 on 7 January 2020.
The largest trade she's ever made was exercising 5,000 units of Enochian Biosciences Inc stock on 7 January 2020 worth over $3,500. On average, Luisa trades about 833 units every 0 days since 2019. As of 7 January 2020 she still owns at least 5,000 units of Enochian Biosciences Inc stock.
You can see the complete history of Ms. Puche stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Luisa Puche biography
Luisa Puche serves as Chief Financial Officer of the Company. Prior to becoming our Chief Financial Officer in January of 2019, Ms. Puche served as a senior accounting and financial advisor and president of Puche Group, LLC, since 2015 where she served in a variety of advisory capacities for both public and private organizations, such as technical accounting consultations; complex technical implementations, M&A transactions; IT Risk assessments; and SOX 404 implementations. Previously, Ms. Puche served in various senior executive roles at Brightstar Corp., a global distributor and service provider in the wireless industry, with public reporting requirements, including as Vice President and Global Controller and Interim Chief Accounting Officer. During her tenure at Brightstar, she was responsible for financial reporting from 55 countries, as well as instrumental in various key transactions including a $1.6B sale of Brightstar to SoftBank. Ms. Puche also worked at Ernst & Young for 10 years. Ms. Puche holds a Bachelor’s of Accounting from Florida International University.
What is the salary of Luisa Puche?
As the Chief Financial Officer of Enochian Biosciences Inc, the total compensation of Luisa Puche at Enochian Biosciences Inc is $508,791. There are 1 executives at Enochian Biosciences Inc getting paid more, with Mark Dybul having the highest compensation of $1,964,450.
How old is Luisa Puche?
Luisa Puche is 57, she's been the Chief Financial Officer of Enochian Biosciences Inc since 2019. There are 4 older and 4 younger executives at Enochian Biosciences Inc. The oldest executive at Enochian Biosciences Inc is Carol Brosgart, 69, who is the Independent Director.
What's Luisa Puche's mailing address?
Luisa's mailing address filed with the SEC is 318 NE 104TH STREET, , MIAMI, FL, 33138.
Insiders trading at Enochian Biosciences Inc
Over the last 7 years, insiders at Enochian Biosciences Inc have traded over $2,106,789 worth of Enochian Biosciences Inc stock and bought 552,919 units worth $3,888,612 . The most active insiders traders include Gregg H Alton, Rene Sindlev oraz Serhat Gumrukcu. On average, Enochian Biosciences Inc executives and independent directors trade stock every 91 days with the average trade being worth of $35,881. The most recent stock trade was executed by Serhat Gumrukcu on 18 May 2022, trading 253,493 units of ENOB stock currently worth $2,027,944.
What does Enochian Biosciences Inc do?
enochian biosciences (formerly dandrit biotech usa inc.) a biopharmaceutical company, focuses on the development and commercialization of novel therapies aimed to change the course of immunotherapy treatments for hiv/aids and cancer. the company’s lead candidate eno-1001 (pre-ind) is a potentially sterilizing cure for hiv/aids. eno-2001 is an hiv vaccine in preclinical stage, and its additional compounds eno-4001 (phase three asset), eno-4002, eno-5001, and eno-3001 are in discovery stages for prevention relapse in colon cancer patients. enochian biosciences is headquartered in los angeles, california.
What does Enochian Biosciences Inc's logo look like?
Complete history of Ms. Puche stock trades at Enochian Biosciences Inc
Enochian Biosciences Inc executives and stock owners
Enochian Biosciences Inc executives and other stock owners filed with the SEC include:
-
Mark Dybul,
Executive Vice Chairman of the Board, Principal Executive Officer -
Luisa Puche,
Chief Financial Officer -
Dr. Mark R. Dybul M.D.,
Chief Exec. Officer & Director -
Luisa Puche,
Chief Financial Officer -
Evelyn D'An,
Independent Director -
James Sapirstein,
Independent Director -
Carl Sandler,
Independent Director -
Henrik Gronfeldt-Sorensen,
Director -
Rene Sindlev,
Independent Chairman of the Board -
Gregg Alton,
Independent Director -
Carol Brosgart,
Independent Director -
Dr. François Binette M.Sc., Ph.D.,
Exec. VP for R&D -
Greg Duczynski Ph.D.,
Sr. VP for Clinical Operations -
Dr. Serhat Gümrükcü,
Co-Founder & Inventor -
Tung Nguyen,
Head of Molecular Biology -
Dr. Wenshi Wang,
Sr. VP of Operations -
Dr. Serhat Gümrükcü,
Co-Founder & Inventor -
Francois Binette,
Executive VP for R&D -
Jayne Mc Nicol,
Director -
Eric Jean Marie Leire,,
-
Carl Forest Sandler,
-
Serhat Gumrukcu,
10% owner -
Anderson Wittekind William,
-
Science Llc Weird,